JP Patent

JP6701237B2 — 前立腺癌およびアンドロゲン受容体関連病態の治療のためのアンドロゲン受容体の調節剤

Assigned to University of California · Expires 2020-05-27 · 6y expired

What this patent protects

Patent listed against Erleada.

Drugs covered by this patent

Patent Metadata

Patent number
JP6701237B2
Jurisdiction
JP
Classification
—
Expires
2020-05-27
Drug substance claim
No
Drug product claim
No
Assignee
University of California
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.